Palatin - רווח נקי למניה אחת בשנים עשר החודשים האחרונים PTN

לוגו של חברה ציבורית Palatin (PTN)

Palatin Technologies (PTN) strictly adheres to FDA regulations regarding the disposal of biomaterials. Growth in license sales and the success of Vyleesi are driving business development. The historical EPS YoY TTM delta visualizes profit dynamics, where the 101.00 level indicates the state of the parameter. The company has earned the trust of medical professionals as an innovator in the therapy of female sexual health and metabolic disorders.

PTN: רווח למניה בשנים עשר החודשים האחרונים Palatin Corp 11.02.2024 - 17.11.2026

PTN (Palatin Technologies): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- פרטי שווי השוק של המנפיק:
הערכת שווי פונדמנטלית של החברה:PTN - Palatin
מוצר סדרתי של Palatin Corp

To minimize investment risks, it is necessary to track the rate of earnings per share generation. This indicator measures the percentage change in net income over a rolling twelve-month period relative to the previous year. By analyzing the year-over-year EPS trend (over 12 months), an investor can visualize the capital efficiency trend. For Palatin Technologies (PTN), this metric reflects the financial outcome of the transition to a clinical research model. Growth in this metric depends directly on the volume of FDA grants and the success of developments in the gastrointestinal sector.